The spectrum of cutaneous T-cell lymphomas: New insights into biology and therapy

Current Opinion in Hematology

Volumn 12, Issue 4, 2005, Pages 273-278

  Querfeld, Christiane ^a   Rosen, Steven T ^a   Guitart, Joan ^a   Kuzel, Timothy M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biologic properties; Cutaneous T cell lymphoma; Molecular and cytogenetic abnormalities; Prognostic factors; Treatment

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEXAROTENE; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE DERIVATIVE; DENILEUKIN DIFTITOX; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GUANINE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; IMIQUIMOD; ISOTRETINOIN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PSORALEN; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID; STEROID; TAZAROTENE; VINCRISTINE; VORINOSTAT;

BEAM THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER STAGING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DISEASE COURSE; ELECTRON BEAM; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HUMAN; IMMUNOMODULATION; INFECTION COMPLICATION; MONOTHERAPY; MYCOSIS FUNGOIDES; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SEZARY SYNDROME; SIDE EFFECT; TUMOR GROWTH;

ANTICARCINOGENIC AGENTS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 23044435701     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000166498.64515.03     Document Type: Review

References (48)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005. [Epub ahead of print.] This paper represents the new consensus classification for CTCL, which is now called the World Health Organization-European Organization for the Research and Treatment of Cancer classification. It describes the clinical, histologic, immunologic, and molecular features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin.
2. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9:3625-3634.
3. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004; 126:81-84. Treg cells suppress the reaction of lymphocytes to tumor antigens, and FoxP3 is expressed on Treg cells and is associated with their activity. This study examined FoxP3 expression on ATLL cells to evaluate their immunosuppressive activity.
4. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10:5494-5500. This paper suggests that CCR4 may play a role in the skin infiltration and epidermotropism of ATLL.
5. Nascimento AF, Pinkus JL, Pinkus GS. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and non-hematopoietic malignant neoplasms. Am J Clin Pathol 2004; 121:709-717. The paper suggests that clusterin expression seems highly specific for ALCL and is therefore of diagnostic value for discriminating ALCL from lymphomatoid papulosis and other cutaneous lymphomas.
6. + may play a role in the skin homing of CD4 / CD56 hematodermic neoplasms.
7. Gniadecki R, Rossen K, Ralfkier E, et al. CD56+ lymphoma with skin involvement: clinicopathologic features and classification. Arch Dermatol 2004; 140:427-436.
8. Notohamiprodjo M, Segerer S, Huss R, et al. CCR10 is expressed in cutaneous T-cell lymphoma. Int J Cancer 2005. [Epub ahead of print.] This paper suggests that CCR10, expressed in malignant lymphocytes, and its ligand CCL27, expressed in keratinocytes, may play a role in the skin infiltration and epidermotropism of malignant T cells.
9. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Circulating clonal CLA+ and CD4+ T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005; 152:258-264. This paper suggests that CCR4, CCR7, and CCR10 expression contributes to lymph node and skin infiltration of malignant T cells representing tumor cell expansions.
10. Poszepczynska-Guigne E, Schiavon V, D'Incan M, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sézary syndrome. J Invest Dermatol 2004; 122:820-823. The study shows that CD158k is selectively expressed on Sézary cells and is therefore of diagnostic and clinical value.
11. Su MW, Dorocicz I, Dragowska WH, et al. Aberrant expression of T-plastin in Sézary cells. Cancer Res 2003; 63:7122-7127.
12. Chen M, Deng A, Crowson AN, et al. Assessment of T-cell clonality via T-cell receptor-gamma rearrangements in cutaneous T-cell-dominant infiltrates using polymerase chain reaction and single-stranded DNA conformational polymorphism assay. Appl Immunohistochem Mol Morphol 2004; 12:373-379. The study shows that polymerase chain reaction and single-stranded DNA conformational polymorphism assay in combination with tissue microdissection enhances the specificity and sensitivity of T-cell clone detection.
13. Assaf C, Hummel M, Steinhoff M, et al. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood 2005; 105:503-510.
14. French LE, Huard B, Wysocka M, et al. Impaired CD40L signaling is a cause of defective IL-12 and TNF-α production in Sézary syndrome: circumvention by hexameric soluble CD40L. Blood 2005; 105:219-225. The paper demonstrates that PBMCs of patients with Sézary syndrome have a defect in interleukin-12 and tumor necrosis factor-α production due to inappropriate anti-CD3 stimulation, with subsequent defect in tumor cell CD40 ligand induction.
15. + Treg cell phenotype and may explain the immunosuppressive nature of the disease.
16. Espinet B, Salido M, Pujol RM, et al. Genetic characterization of Sezary's syndrome by conventional cytogenetics and cross-species color banding fluorescent in situ hybridization. Haematologica 2004; 89:165-173.
17. Wain EM, Mitchell TJ, Russell-Jones R, Whittaker S. Fine mapping of chromosome 10q deletions in mycosis fungoides and Sezary syndrome: identification of two discrete regions of deletion at 10q23.33-24.1 and 10q24.33-25.1. Genes Chromosomes Cancer 2005; 42:184-192.
18. Rübben A, Kempf W, Kadin ME, et al. Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma. Exp Dermatol 2004; 13:472-483. This study analyzed 10 patients with mycosis fungoides/Sézary syndrome for genetic instability. Microsatellite instability was found in microdissected tumor tissue from skin biopsies of patients with early and advanced disease. Tumor subclones of mycosis fungoides were found in early-stage disease, suggesting a multilineage progression.
19. Scarisbrick JJ, Mitchell TJ, Calonje E, et al. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003; 121:894-901.
20. 6-methylguanine DNA methyltransferase promoter inactivation may affect responses to alkylating agents.
21. Mao X, Orchard G, Lillington DM, et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004; 151:546-556.
22. Sommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma: evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18:1288-1295. The authors observed in-vivo activation of STAT3 in mycosis fungoides tumors but not in early stages and suggest that STAT3 protects tumor cells from apoptosis in vitro.
23. Brender C, Lovato P, Sommer VH, et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFN-alpha. Leukemia 2005; 19:209-213. The authors reported that SOCS-3, a Stat3-induced negative regulator, does not inhibit Stat3 activation, growth, and survival in CTCL.
24. van Doom R, Dijkman R, Vermeer MH, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004; 64:5578-5586.
25. Wang S, Li N, Heald P, et al. Flow cytometric DNA ploidy analysis of peripheral blood from patients with Sézary syndrome: detection of aneuploid neoplastic T cells in the blood is associated with large cell transformation in tissue. Am J Clin Pathol 2004; 122:774-782.
26. Tancrede-Bohin E, Ionescu MA, de La Salmoniere P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 2004; 140:1057-1061.
27. Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 2005; 52:32-39.
28. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early stage cutaneous T-cell lymphoma who achieved complete remission on PUVA monotherapy. Arch Dermatol 2005; 141:305-311. This paper reported on long-term results of 66 patients with clinical stage IA-IIA treated with PUVA. Thirty percent to 50% of patients remain disease-free for close to 10 years, but late relapses occurred. The long-term survival is not affected by relapse status.
29. Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol 2004; 50:600-607.
30. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52:275-280.
31. Nistico S, Costanzo A, Saraceno R, Chimenti S. Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides. Br J Dermatol 2004; 151:877-879.
32. Passeron T, Zakaria W, Ostovari N. Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides. Arch Dermatol 2004; 140:1291-1293.
33. Guanche AD, Bohjanen K, Tope WD. Surgical treatment of obstructive palpebral tumors in d'emblee variant of cutaneous T-cell lymphoma. Dermatol Surg 2004; 30:1568-1571.
34. Ysebaert L, Truc G, Dalac S, et al. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 2004; 58:1128-1134.
35. Mebazaa A, Dupuy A, Rybojad M, et al. ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients. Hematol J 2005; 5:553-558.
36. Qualigno P, Fierro MT, Rossotto GL, et al. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 2004; 150:327-336.
37. Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol 2004; 51:25-32. This retrospective study summarized and compared a phase II experience with the RAR receptor agonist ATRA with the clinical use of the RXR receptor agonist bexarotene in patients with relapsed mycosis fungoides/Sézary syndrome. Both showed low benefit with differences in toxicities.
38. el-Azhary RA, Bouwhuis SA. Oral bexarotene in a therapy-resistant Sezary syndrome patient: observations on Sezary cell compartmentalization. Int J Dermatol 2005; 44:25-28. A patient was presented with gradual improvement of erythema, although an increase in absolute Sézary cell count was observed. It is speculated that bexarotene downregulates E-selectin on endothelial cells that alters the trafficking of lymphocyte subsets from the skin compartment to the lymph nodes or blood.
39. Tsimberidou AM, Giles F, Romaguera J, et al. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 2004; 100:574-580.
40. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004; 50:375-379.
41. Jones D, Ibrahim S, Patel K, et al. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin Cancer Res 2004; 10:5587-5594. This study shows that CD25 expression, highly expressed in epidermotropic tumor cells, decreases when tumor cells involve lymph nodes similar to cutaneous lymphocyte antigen expression. This will have implications for interleukin-2R-targeted immune therapy.
42. Dearden C. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm 2004; 19:391-398.
43. Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004; 104:655-658.
44. Herbert KE, Spencer A, Grigg A, et al. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34:521-525. This series of three cases reported on outcomes in patients treated with reduced-intensity allogeneic transplantation. Published experience with this approach is limited.
45. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103:4636-4643. This paper reports the in-vitro effects of histone deacetylase inhibitors in the CTCL cell line HuT-78. Depsipeptide and analogues increased histone acetylation and induced p21 expression and apoptosis. In addition, the observed increased expression of interleukin-2R subunits and MDR-1 in these tumor cells increased the sensitivity for denileukin diftitox treatment.
46. Duvic M, Talpur R, Chiao J. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Blood 2003; 102:179a.
47. Wysocka M, Benoit BM, Newton S, et al. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004; 104:4142-4149. The paper focuses on the immune effects of synthetic oligodeoxynucleotides with CpG motifs following binding to the Toll-like receptor 9 on dendritic cells. A marked induction of interferon-α release following culture with CpG-ODN was observed in PMBCs from Sézary syndrome patients, with similar effects on natural killer cells and CD8 T cells.
48. Kim Y, Girardi M, Duvic M, et al. TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909. Blood 2004; 104:212a.